Wide Ranks

HAE

Haemonetics Corporation

87.89

Top Statistics
Market Cap 4 B Forward PE 16.42 Revenue Growth 8.60 %
Current Ratio 3.49 Trailing PE 36.47 Earnings Growth 37.50 %
Profit Margins 9.10 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 17.28 Enterprise / Revenue 3.99 Price To Sales Trailing12 Months 3.24
Profitability
Profit Margins 9.10 % Operating Margins 16.44 %
Balance Sheet
Total Cash 300 M Total Cash Per Share 5.97 Total Debt 1 B
Total Debt To Equity 149.62 Current Ratio 3.49 Book Value Per Share 17.44
All Measures
Short Ratio 674.00 % Message Board Id finmb_94613 Shares Short Prior Month 5 M
Return On Equity 0.1397 City Boston Uuid c6560537-1af6-3c75-98ee-3920a143ded3
Previous Close 88.53 First Trade Date Epoch Utc 673 M Book Value 17.44
Beta 0.3210 Total Debt 1 B Volume 430972
Price To Book 5.04 Last Split Date 1 B Fifty Two Week Low 70.25
Total Cash Per Share 5.97 Total Revenue 1 B Shares Short Previous Month Date 1 B
Target Median Price 113.50 Max Age 86400 Recommendation Mean 1.90
Sand P52 Week Change 0.3133 Operating Margins 16.44 % Target Mean Price 110.80
Net Income To Common 123 M Ask 88.30 Short Percent Of Float 0.1442
Implied Shares Outstanding 50 M Last Fiscal Year End 1 B Trailing Peg Ratio 159.57 %
Average Daily Volume10 Day 574060 Average Volume10days 574060 Total Cash 300 M
Next Fiscal Year End 1 B Revenue Per Share 26.77 Held Percent Insiders 0.0089
Ebitda Margins 23.08 % Trailing PE 36.47 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 88.53 Target Low Price 85.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 79.48 Open 89.04
Free Cashflow 85 M State MA Dividend Yield 0.00 %
Return On Assets 0.0588 Time Zone Short Name EST Trailing Eps 2.41
Day Low 87.53 Address1 125 Summer Street Shares Outstanding 50 M
Price Hint 2 Target High Price 125.00 Website https://www.haemonetics.com
52 Week Change 0.0868 Average Volume 625287 Earnings Quarterly Growth 35.80 %
Forward Eps 5.34 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 187.50 % Last Split Factor 2:1 Regular Market Day High 89.69
Is_sp_500 False Profit Margins 9.10 % Debt To Equity 149.62
Fifty Two Week High 97.97 Day High 89.69 Shares Short 4 M
Regular Market Open 89.04 Industry Key medical-instruments-supplies Bid 87.56
Earnings Growth 37.50 % Enterprise To Revenue 3.99 Revenue Growth 8.60 %
Shares Percent Shares Out 0.0912 Operating Cashflow 84 M Currency USD
Time Zone Full Name America/New_York Market Cap 4 B Is_nasdaq_100 False
Zip 02110 Quote Type EQUITY Industry Medical Instruments & Supplies
Long Name Haemonetics Corporation Regular Market Day Low 87.53 Held Percent Institutions 1.14
Current Price 87.89 Enterprise To Ebitda 17.28 Financial Currency USD
Current Ratio 3.49 Gross Margins 54.68 % Industry Disp Medical Instruments & Supplies
Number Of Analyst Opinions 10 Country United States Float Shares 49 M
Two Hundred Day Average 82.23 Ir Website http://phx.corporate-ir.net/phoenix.zhtml?c=72118&p=irol-irhome Enterprise Value 5 B
Price To Sales Trailing12 Months 3.24 Forward PE 16.42 Regular Market Volume 430972
Ebitda 314 M Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha 
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally.

The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system.

In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions.

Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen.

The company sells its products through direct sales force, independent distributors, and sales representatives.

Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.